Trials / Unknown
UnknownNCT00930735
The Prognostic Significance of Fibrosis Detection in Cardiomyopathy
The Prognostic Significance of Fibrosis Detection in Ischemic and Non-ischemic Cardiomyopathy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,000 (estimated)
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The presence of scar within heart muscle can act as a substrate for abnormal rhythm problems and lead to the developement of heart failure Clinical significance Correlation with biomarkers and genetic markers
Detailed description
Patients will undergo cardiovascular magnetic resonance (CMR) to include measurement of left ventricular volumes, ejection fraction, detection of inflammation (via STIR sequences) where appropriate, early gadolinium enhancement, late gadolinium enhancement, first pass perfusion using pharmacological stress imaging (contraindications to include comorbidities that do not permit pharmacological stress agents e.g. severe asthma, severe or symptomatic aortic stenosis)
Conditions
Timeline
- Start date
- 2000-01-01
- Primary completion
- 2020-04-30
- Completion
- 2025-07-01
- First posted
- 2009-06-30
- Last updated
- 2018-04-23
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00930735. Inclusion in this directory is not an endorsement.